In the setting of the biopsy-proven histology of primary NSCLC, patients with adenocarcinoma and/or known high-risk oncogenic driver mutations (EGFR, ALK), as well as patients of young age, might be considered to undergo BI due to the higher incidence of BM in this population [72]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.